Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Prostate cancer immunotherapy: where are we and where are we going?

De Velasco MA, Uemura H.

Curr Opin Urol. 2018 Jan;28(1):15-24. doi: 10.1097/MOU.0000000000000462.

PMID:
29095729
2.

Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

Sakai K, Ukita M, Schmidt J, Wu L, De Velasco MA, Roter A, Jevons L, Nishio K, Mandai M.

Cancer Lett. 2017 Oct 1;405:22-28. doi: 10.1016/j.canlet.2017.07.013. Epub 2017 Jul 19.

3.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.

Int J Oncol. 2017 Jun;50(6):2049-2058. doi: 10.3892/ijo.2017.3961. Epub 2017 Apr 18.

PMID:
28440469
4.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.

5.

MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.

6.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Sci. 2016 Nov;107(11):1667-1676. doi: 10.1111/cas.13071.

7.

Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.

Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K.

Oncotarget. 2016 Aug 2;7(31):49091-49098. doi: 10.18632/oncotarget.10077.

8.

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14.

9.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K.

Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20.

10.

Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K.

Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24.

PMID:
26916220
11.

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.

Oncotarget. 2016 Mar 29;7(13):15959-76. doi: 10.18632/oncotarget.7557.

12.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Clin Cancer Res. 2016 Jul 15;22(14):3663-71. doi: 10.1158/1078-0432.CCR-15-2093. Epub 2016 Jan 29.

13.

Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.

Yoshioka Y, Togashi Y, Chikugo T, Kogita A, Taguri M, Terashima M, Mizukami T, Hayashi H, Sakai K, de Velasco MA, Tomida S, Fujita Y, Tokoro T, Ito A, Okuno K, Nishio K.

Cancer. 2015 Dec 15;121(24):4359-68. doi: 10.1002/cncr.29676. Epub 2015 Oct 21.

14.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.

Int J Oncol. 2015 Aug;47(2):499-505. doi: 10.3892/ijo.2015.3050. Epub 2015 Jun 16.

PMID:
26081723
15.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22. No abstract available.

PMID:
26002608
16.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.

PLoS One. 2015 May 8;10(5):e0121891. doi: 10.1371/journal.pone.0121891. eCollection 2015.

17.

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.

Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

J Transl Med. 2015 May 8;13:150. doi: 10.1186/s12967-015-0509-x.

18.

New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

Int Immunopharmacol. 2015 May;26(1):133-8. doi: 10.1016/j.intimp.2015.03.023. Epub 2015 Mar 27.

PMID:
25819666
19.

Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.

Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H.

Asian Pac J Cancer Prev. 2015;16(5):1827-31.

20.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.

Lung Cancer. 2015 Apr;88(1):16-23. doi: 10.1016/j.lungcan.2015.01.027. Epub 2015 Feb 7.

PMID:
25704955
21.

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.

Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K.

Springerplus. 2015 Jan 5;4:7. doi: 10.1186/2193-1801-4-7. eCollection 2015.

22.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.

Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.

PMID:
25502629
23.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K.

Cancer Lett. 2015 Jan 28;356(2 Pt B):819-27. doi: 10.1016/j.canlet.2014.10.037. Epub 2014 Nov 4.

PMID:
25449777
24.

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.

Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.

J Thorac Oncol. 2015 Jan;10(1):93-101. doi: 10.1097/JTO.0000000000000353.

25.

MEK inhibitor for gastric cancer with MEK1 gene mutations.

Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K.

Mol Cancer Ther. 2014 Dec;13(12):3098-106. doi: 10.1158/1535-7163.MCT-14-0429. Epub 2014 Sep 24.

26.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.

Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014.

27.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.

Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.

Int J Oncol. 2014 Oct;45(4):1430-6. doi: 10.3892/ijo.2014.2574. Epub 2014 Aug 1.

28.

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.

Terashima M, Fujita Y, Togashi Y, Sakai K, De Velasco MA, Tomida S, Nishio K.

Oncotarget. 2014 Aug 30;5(16):7040-50.

29.

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.

Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.

30.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.

Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H, Yasuda T, Shiozaki H, Nishio K.

Oncotarget. 2014 May 30;5(10):2962-73.

31.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.

Togashi Y, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Ito A, Kudo M, Nishio K.

Mol Cancer. 2014 May 27;13:126. doi: 10.1186/1476-4598-13-126.

32.

Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.

Fujita Y, Koinuma S, De Velasco MA, Bolz J, Togashi Y, Terashima M, Hayashi H, Matsuo T, Nishio K.

PLoS One. 2014 Apr 10;9(4):e94772. doi: 10.1371/journal.pone.0094772. eCollection 2014.

33.

Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition.

Tsuji H, Shimizu N, Nozawa M, Umekawa T, Yoshimura K, De Velasco MA, Uemura H, Khan SR.

Urolithiasis. 2014 Jun;42(3):195-202. doi: 10.1007/s00240-014-0649-0. Epub 2014 Mar 12.

34.

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.

Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K.

Oncogene. 2015 Jan 8;34(2):199-208. doi: 10.1038/onc.2013.547. Epub 2013 Dec 23.

PMID:
24362523
35.

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.

Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, Matsumoto K, De Velasco MA, Kato H, Hayashi H, Yoshida S, Kimura H, Maniwa Y, Nishio W, Sakai Y, Ohbayashi C, Kotani Y, Nishimura Y, Nishio K.

Cancer Med. 2013 Apr;2(2):144-54. doi: 10.1002/cam4.68. Epub 2013 Mar 1.

36.

Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis.

Shimizu N, De Velasco MA, Umekawa T, Uemura H, Yoshikawa K.

Int J Urol. 2013 Nov;20(11):1136-43. doi: 10.1111/iju.12119. Epub 2013 Feb 19.

37.

Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.

De Velasco MA, Uemura H.

Adv Urol. 2012;2012:419348. doi: 10.1155/2012/419348. Epub 2012 Feb 21.

38.

Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.

Fujita Y, Islam R, Sakai K, Kaneda H, Kudo K, Tamura D, Aomatsu K, Nagai T, Kimura H, Matsumoto K, de Velasco MA, Arao T, Okawara T, Nishio K.

Invest New Drugs. 2012 Oct;30(5):1878-86. doi: 10.1007/s10637-011-9749-7. Epub 2011 Sep 13.

PMID:
21912888
39.

Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer.

Kaneda H, Arao T, Matsumoto K, De Velasco MA, Tamura D, Aomatsu K, Kudo K, Sakai K, Nagai T, Fujita Y, Tanaka K, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K.

Br J Cancer. 2011 Oct 11;105(8):1210-7. doi: 10.1038/bjc.2011.348. Epub 2011 Sep 6.

40.

A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.

Zennami K, Yoshikawa K, Kondo E, Nakamura K, Upsilonamada Y, De Velasco MA, Tanaka M, Uemura H, Shimazui T, Akaza H, Saga S, Ueda R, Honda N.

Oncol Rep. 2011 Aug;26(2):327-33. doi: 10.3892/or.2011.1290. Epub 2011 Apr 29.

PMID:
21567093
41.

Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.

Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K.

Clin Cancer Res. 2011 Mar 15;17(6):1373-81. doi: 10.1158/1078-0432.CCR-09-2755. Epub 2010 Dec 3.

42.

Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress.

Hayashi T, De Velasco MA, Saitou Y, Nose K, Nishioka T, Ishii T, Uemura H.

Int J Urol. 2010 Dec;17(12):989-95. doi: 10.1111/j.1442-2042.2010.02644.x. Epub 2010 Oct 14.

43.

FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.

Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K.

Cancer Res. 2010 Mar 1;70(5):2053-63. doi: 10.1158/0008-5472.CAN-09-2161. Epub 2010 Feb 9.

44.

Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.

Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, Yamada A, Itoh K.

Cancer Sci. 2010 Mar;101(3):601-8. doi: 10.1111/j.1349-7006.2009.01459.x. Epub 2009 Dec 7.

45.

Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.

Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, Fujimoto K, Hirao K, Konishi N.

Cancer Sci. 2010 Jan;101(1):155-60. doi: 10.1111/j.1349-7006.2009.01379.x. Epub 2009 Oct 6.

46.

Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer.

Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N.

Cancer Sci. 2009 Jul;100(7):1248-54. doi: 10.1111/j.1349-7006.2009.01174.x. Epub 2009 Apr 21.

47.

GFP image analysis in the mouse orthotopic bladder cancer model.

De Velasco MA, Tanaka M, Anai S, Tomioka A, Nishio K, Uemura H.

Oncol Rep. 2008 Sep;20(3):543-7.

PMID:
18695904
48.

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation.

Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y.

Mol Cancer Ther. 2008 Jul;7(7):1864-70. doi: 10.1158/1535-7163.MCT-07-2198.

49.

Tumor vaccines in renal cell carcinoma.

Uemura H, De Velasco MA.

World J Urol. 2008 Apr;26(2):147-54. doi: 10.1007/s00345-008-0246-3. Epub 2008 Mar 12.

PMID:
18335222

Supplemental Content

Loading ...
Support Center